When One Drug Isn't Enough: What a 2026 Meta-Analysis Found About Combination Therapy for Children With IBD

IBD (Crohn's disease and ulcerative colitis) can begin in childhood. Paediatric-onset IBD is well recognised, with a significant proportion of diagnoses made in people under 18 worldwide, and the disease frequently follows a more aggressive course in younger patients compared to adult-onset disease (Huo BL et al., World J Pediatr, 2026). For many children, standard single-drug treatment (monotherapy) brings the disease under adequate control. But a meaningful proportion do not respond, or lose response over time, and that is when treatment decisions become significantly harder.

Combination therapy, using two immunomodulating drugs together such as two biologics or a biologic paired with a targeted small molecule, is an emerging strategy for these treatment-resistant cases. A 2026 systematic review and meta-analysis published in World Journal of Pediatrics set out to pool the available evidence on how well this approach works in children and adolescents with IBD, and what the safety profile looks like.

What the Review Did

Researchers searched multiple medical databases through January 1, 2026, looking for studies that reported outcomes of dual biologic or biologic-plus-small-molecule therapy in paediatric IBD patients. Twelve studies met their inclusion criteria. Across those 12 studies, 217 paediatric patients were included; all had previously failed standard monotherapy and were placed on a combination regimen as their next treatment step.

The most common combination regimens were an anti-TNF-alpha agent (such as infliximab or adalimumab) paired with vedolizumab (37.2% of cases) or with ustekinumab (28.6%). A smaller proportion received combinations that included tofacitinib or upadacitinib, two targeted small molecules that work through JAK inhibition rather than targeting a specific immune protein (Huo BL et al., World J Pediatr, 2026).

The analysis measured rates of clinical remission, endoscopic remission, and corticosteroid-free remission, as well as adverse event rates.

What the Analysis Found

Clinical remission: The pooled clinical remission rate was 69% (95% confidence interval [CI]: 52%-84%). Across all 12 studies, roughly two-thirds of the children and adolescents on combination therapy achieved clinical remission, meaning their symptoms came under control. The confidence interval spans a wide but generally encouraging range.

Endoscopic remission: The pooled endoscopic remission rate was 51% (95% CI: 18%-83%). Endoscopic remission, where inflammation is no longer visible when the gut lining is directly examined, is a more demanding standard than symptom control. The very wide confidence interval here reflects substantial variation between the included studies; this figure requires cautious interpretation. Roughly half of patients achieving mucosal healing in a treatment-resistant population is clinically meaningful, but the uncertainty is real.

Corticosteroid-free remission: 66% of patients (95% CI: 41%-88%) achieved corticosteroid-free remission. Reducing steroid exposure is a particularly important goal in paediatric IBD. The NHS notes that Crohn's disease in children can cause delayed growth and delayed puberty if not treated properly (NHS: Crohn's disease, NHS.UK). Long-term corticosteroid use compounds those developmental risks, making steroid-free remission a key clinical target.

Safety: The overall adverse event rate was 17% (95% CI: 6%-31%). Serious adverse events occurred in 11% of patients (95% CI: 4%-20%). Importantly, no malignancies and no deaths were reported across any of the included studies. Inflammatory biomarkers including C-reactive protein, fecal calprotectin, erythrocyte sedimentation rate, and disease activity indices (PCDAI for Crohn's disease; PUCAI for ulcerative colitis) all showed significant improvement.

Why This Matters

For families of children with IBD that has not responded to first-line single-drug treatment, the practical question is: what comes next, and what can the evidence say about how well it is likely to work?

This meta-analysis provides the first pooled answer to that question. A 69% clinical remission rate in patients who had already failed standard monotherapy is a meaningful data point. It tells families and clinicians that combination therapy is not a long shot in this setting; for most children in this analysis, it did produce a treatment response.

The absence of malignancies or deaths across all included studies is also notable. Concerns about long-term immunosuppression risk, particularly in children who still have decades of life ahead, are a legitimate part of any treatment conversation. The current evidence does not resolve those long-term questions, but the short-to-medium-term safety signal in these studies is reassuring.

The authors of the meta-analysis describe dual therapy as "effective and relatively safe" for paediatric patients with treatment-resistant IBD, while emphasising that high-quality prospective controlled trials are still needed to fully characterise long-term outcomes.

How to Read These Numbers

Two caveats are important. First, 217 total patients across 12 studies is a small evidence base for definitive conclusions. These numbers are enough to identify a signal and calculate a pooled estimate, but not yet enough for high-confidence population-level guidance. Second, all included patients had already failed monotherapy; this is not a result that generalises to all children newly diagnosed with IBD.

The endoscopic remission confidence interval (18%-83%) in particular reflects genuine heterogeneity across studies. Until larger, randomised prospective trials are completed, the variation in outcomes reported across centres will persist.

What this meta-analysis does provide is a concrete starting point for a conversation with a specialist. For a family navigating treatment-resistant paediatric IBD, knowing that approximately two in three children in comparable situations achieved clinical remission on combination therapy is clinically relevant context, even if it is not a guarantee.

Sources

• Huo BL, Zhao AL, Liu W, Ma LF, Luo XR. "Dual biologics or combination therapy with small molecules in pediatric inflammatory bowel disease: a systematic review and meta-analysis." World Journal of Pediatrics. 2026 Jul 1. PubMed 42387245
• NHS. "Crohn's disease." NHS.UK. NHS.UK